NPY and prostate cancer: In contrast, Ruscica et al. discovered that a Y1 receptor antagonist reversed NPY-mediated tumor growth inhibition in prostate cancer [42], indicating that the NPY/Y1 receptor axis may contribute to tumor growth suppression; thus, FAP may modulate the immune microenvironment and have different effects on tumor growth through the NPY system in various cancers.